PF-5274857 free base is a small molecule inhibitor that targets the PIM kinase family. This kinase family plays an essential role in regulating cell growth and survival, making it a potential therapeutic target for cancer treatment.
Chemical name: N-(5-((4-(morpholin-4-yl)phenyl)amino)pyridin-2-yl)-3-(trifluoromethyl)benzamide
Molecular formula: C24H21F3N4O2
Formula weight: 450.44 g/mol
CAS No: 1373615-35-0
Top ten keywords from Google and Synonyms:
Health benefits of this product: Studies have shown that PF-5274857 has potent anti-tumor effects in a variety of cancers, including leukemia, lymphoma, prostate, and breast cancer. It works by inhibiting the PIM kinase family, which is important in tumor growth and progression. Additionally, PF-5274857 may also have neuroprotective effects and could potentially be used to treat neurological disorders such as Alzheimer's disease.
Potential effects: As a PIM kinase inhibitor, PF-5274857 has the potential to slow or stop tumor growth in a variety of cancers. It may also have neuroprotective effects that could be useful in treating neurological disorders. However, more research is needed to fully understand the potential effects of PF-5274857.
Product mechanism: PF-5274857 works by inhibiting the PIM kinase family. This kinase family plays an essential role in regulating cell growth and survival. In cancer cells, this pathway is often overactive, leading to uncontrolled cell growth and tumor formation. PF-5274857 binds to the active site of the PIM kinase family and prevents its activity. This leads to a reduction in the activity of the pathway and subsequently slows or stops tumor growth.
Safety: PF-5274857 has been shown to be generally safe in preclinical studies, but more research is needed to fully understand its safety profile in humans. As with any drug, there is a risk of adverse effects, especially when used at high doses or for prolonged periods. Patients should consult their healthcare provider before beginning treatment with PF-5274857.
Side effects: The most common side effect of PF-5274857 in preclinical studies was mild gastrointestinal upset, including nausea and diarrhea. Other potential side effects may include liver toxicity, skin rash, and bone marrow suppression. Patients should report any severe or persistent side effects to their healthcare provider.
Dosing information: PF-5274857 dosing varies depending on the indication and patient factors such as age, weight, and overall health. It is typically administered orally, either alone or in combination with other cancer drugs. Patients should follow their healthcare provider's dosing instructions carefully and report any missed doses or changes in symptoms.
Conclusion: PF-5274857 is a promising drug candidate for the treatment of cancer and neurological disorders. Its ability to inhibit the PIM kinase family makes it a potentially valuable tool in slowing or stopping tumor growth. However, more research is needed to fully understand its potential effects and safety profile in humans. Patients should consult their healthcare provider before beginning treatment with PF-5274857 and report any severe or persistent side effects
